Why Inozyme Pharma Shares Are Jumping Today
Inozyme Pharma Inc (NASDAQ:INZY) announced preliminary biomarker, safety, and pharmacokinetic (PK) data from the first three patients treated in the Phase 1 portion of its Phase 1/2 trial of INZ-701 in ENPP1 Deficiency. ENPP1 Deficiency manifests generalized arterial calcification of infancy (GACI), characterized by extensive vascular calcification and overgrowth of smooth muscle cells…
Benzinga ·
Benzinga
